Assistant Professor of Breast Radiation Oncology at MD Anderson Cancer Center @MDAndersonNews | Passions: translational research & #meded! Opinions are my own.
It was an honor to present at the @RushCancer@UTMDAnderson#breastcancer symposium in Chicago today with my brilliant #bcsm colleagues Drs @ChelainG & Azadeh Nasrazadani. So lucky to work with such incredible women in oncology.
#ThreeGoodThings:
1️⃣ 11,000+ walked the @MDAndersonNews Boot Walk and raised over $2M to fund research to #EndCancer
2️⃣ #Radonc baby shower welcoming the next generation of #babiesWhoCutie
3️⃣ local market last night! I bought some mugs, pins, and a tiny piece of framed art 🖼️
Radiation oncologists are trained to deliver safe, high-precision radiotherapy as part of a #cancer care team. We follow the best available evidence & develop customized, cost-effective plans. Science guides our treatments, but humanity guides our practice. 1/2
We looked back at ~1000 patients with lung cancer and melanoma treated with immune checkpoint inhibitors (ICIs). We found that those who happened to received COVID mRNA vaccines within 100 days of starting ICIs lived much longer than those who did not receive the vaccine.
Looking forward to discussing the option for repeat breast conservation and re-irradiation for our patients who experience locoregional recurrence at #SABCS25! Couldn’t be more humbled to present alongside @BOffersen and Dr. Broyles in a panel led by @JBStraussMD. @MDAndersonNews
Refining Local Therapy in Multi-disciplinary Care:
Chelain Goodman, Birgitte Offersen, and Justin Broyles will address this topic in an educational session at #SABCS25 (December 9-12). Learn more:
https://t.co/TaeTPB8oGA
@ChelainG@BOffersen
As part of the @IJROBP special editions on Adaptive Radiation Therapy, the @ASTRO_org workforce committee put together a commentary discussing the potential workforce implications: https://t.co/JNXY2If2Jp
@ChelainG@JamesBatesMD@SameerKeoleMD
Exciting presentation by Dr. Goodman @ChelainG demonstrating a ⬆️ rate of CTC clearance following neo & adjuvant radiotherapy in non-metastatic T3+ and/or N+ BC - looking forward to the next phase to assess CTC’s potential as a surrogate survival endpoint #ESTRO25@ESTRO_RT
1/🧵What do graduating #RadOnc residents think about their training?
We analyzed 5 years of ARRO data (820 PGY5s; response rate ~87%) — the largest study to date.
The good, the no-so-good, and the growing interest in competency based #MedEd@ARRO_org
https://t.co/xlH4UiJJ4E
We’re hiring! @MDAndersonNews seeks a visionary Chair of Breast Medical Oncology to lead cutting-edge patient care and research. Ready to shape the future of breast cancer care? Learn more & apply: https://t.co/o7eOfd7wsN Oncology Leadership #EndCancer#OncSurgery
With over 16 classification systems, osteoradionecrosis (ORN) has been a challenging RT-related toxicity to diagnose and manage. I’m excited to share the multidisciplinary ORAL Consortium’s consensus guidelines on standardized data capture to enhance interoperability & diagnosis!
Amazing talk by @KHoffmanMD@MDAndersonNews yesterday. An accomplished female leader in an often male field of GU #radonc she comes from an amazing legacy of women in medicine. Her aunt was one of the first female MDs in the country!
SUPREMO does not answer role of PMRT after SLNB without ALND.
- All N+ had ALND - does not address N+ patients s/p SLNB only.
- Per AMAROS, PMRT associated with reduced risk of lymphedema vs ALND.
So, PMRT still the treatment of choice post SLNB for int risk N+ pts?
#SABCS24
Supremo trial 10 yr data PMRT vs not in N0, or 1-3 nodes showing no significant benefit to PMRT for any endpoint/CW benefit significant but small. Important context, all had axlnd. Will future include targeted ax radiation? Does this apply after SLNbx? #SABCS24
Omission reaches also systemic treatments for breast cancer:
EUROPA trial preliminary results with superb @Icro_Meattini presentation at #SABCS24 shows RT might be a better approach for women aged 70+ with luminal A-like early breast cancer #radonc#bcsm